{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:11:43Z","timestamp":1789463503491,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00175-w","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:45:25Z","timestamp":1789454725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy"],"prefix":"10.1007","volume":"61","author":[{"given":"Dong Won","family":"Baek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"6","key":"175_CR1","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.","journal-title":"Blood Cancer J"},{"issue":"7","key":"175_CR2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ajh.27708","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Jabbour E. Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2025;100(7):1205\u201331.","journal-title":"Am J Hematol"},{"issue":"13","key":"175_CR3","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/10428194.2024.2387728","volume":"65","author":"MS Schwartz","year":"2024","unstructured":"Schwartz MS, Muffly LS. Predicting relapse in acute lymphoblastic leukemia. Leuk Lymphoma. 2024;65(13):1934\u201340.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"175_CR4","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005;106(12):3760\u20137.","journal-title":"Blood"},{"issue":"8","key":"175_CR5","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189\u201397.","journal-title":"Blood"},{"issue":"4","key":"175_CR6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood. 2008;111(4):1827\u201333.","journal-title":"Blood"},{"issue":"2","key":"175_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","volume":"115","author":"AV Moorman","year":"2010","unstructured":"Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206\u201314.","journal-title":"Blood"},{"issue":"1","key":"175_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44313-024-00007-9","volume":"59","author":"I Frikha","year":"2024","unstructured":"Frikha I, Frikha R, Medhaffer M, Charfi H, Turki F, Elloumi M. Impact of CYP1A1 variants on the risk of acute lymphoblastic leukemia: evidence from an updated meta-analysis. Blood Res. 2024;59(1):9.","journal-title":"Blood Res"},{"issue":"23","key":"175_CR9","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","volume":"5","author":"G Richard-Carpentier","year":"2021","unstructured":"Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, et al. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021;5(23):5415\u20139.","journal-title":"Blood Adv"},{"issue":"11","key":"175_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y, Pei D, et al. Targetable kinase-activating lesions in Philadelphia chromosome-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"175_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","volume":"129","author":"N Jain","year":"2017","unstructured":"Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572\u201381.","journal-title":"Blood"},{"issue":"29","key":"175_CR12","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.23.02238","volume":"42","author":"T Chang","year":"2024","unstructured":"Chang T, Chen W, Qu C, Cheng Z, Hedges D, Elsayed A, et al. Genomic determinants of outcome in acute lymphoblastic leukemia. J Clin Oncol. 2024;42(29):3491\u2013503.","journal-title":"J Clin Oncol"},{"issue":"7","key":"175_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/jamaoncol.2025.0613","volume":"11","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Aldoss I, Jabbour E. Management of adult acute lymphoblastic leukemia: a review. JAMA Oncol. 2025;11(7):771\u20138.","journal-title":"JAMA Oncol"},{"issue":"4","key":"175_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"175_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"14","key":"175_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.2023022922","volume":"145","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Roddie C. The present and future of CAR T-cell therapy for adult B-cell ALL. Blood. 2025;145(14):1485\u201397.","journal-title":"Blood"},{"issue":"8","key":"175_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi P, Soddu S, Messina M, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024;42(8):881\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"175_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023;98(3):493\u2013501.","journal-title":"Am J Hematol"},{"issue":"12","key":"175_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla M, Dagdan E, Zaliova M, M\u00f6ricke A, Palmi C, Cazzaniga G, et al. IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36(12):1240\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"175_CR20","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/bjh.19012","volume":"202","author":"FG Haddad","year":"2023","unstructured":"Haddad FG, Kourie HR, Saleh K. Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia. Br J Haematol. 2023;202(6):1084\u20136.","journal-title":"Br J Haematol"},{"issue":"5","key":"175_CR21","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2352-3026(23)00064-9","volume":"10","author":"NJ Short","year":"2023","unstructured":"Short NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol. 2023;10(5):e382\u20138.","journal-title":"Lancet Haematol"},{"issue":"6","key":"175_CR22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"S Giebel","year":"2019","unstructured":"Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54(6):798\u2013809.","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"175_CR23","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood. 2009;113(19):4489\u201396.","journal-title":"Blood"},{"issue":"24","key":"175_CR24","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela J, Abbal C, Huguet F, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711\u20139.","journal-title":"Blood"},{"issue":"3","key":"175_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","volume":"1","author":"F Ravandi","year":"2016","unstructured":"Ravandi F, Othus M, O\u2019Brien SM, Forman SJ, Ha CS, Wong J, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016;1(3):250\u20139.","journal-title":"Blood Adv"},{"issue":"5","key":"175_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41375-021-01496-8","volume":"36","author":"Y Sasaki","year":"2022","unstructured":"Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022;36(5):1253\u201360.","journal-title":"Leukemia"},{"issue":"1","key":"175_CR27","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24\u201334.","journal-title":"Lancet Haematol"},{"issue":"1","key":"175_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","volume":"18","author":"NJ Short","year":"2025","unstructured":"Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, et al. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J Hematol Oncol. 2025;18(1):55.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"175_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242\u201352.","journal-title":"Nat Genet"},{"issue":"2","key":"175_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2643-3230.BCD-22-0154","volume":"4","author":"R Kim","year":"2023","unstructured":"Kim R, Bergugnat H, Larcher L, Duchmann M, Passet M, Gachet S, et al. Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis. Blood Cancer Discov. 2023;4(2):134\u201349.","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"175_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/2643-3230.BCD-23-0006","volume":"4","author":"R Saiki","year":"2023","unstructured":"Saiki R, Ogawa S. Adult low-hypodiploid acute lymphoblastic leukemia evolves from TP53-mutated clonal hematopoiesis. Blood Cancer Discov. 2023;4(2):102\u20135.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"175_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01350-5","volume":"15","author":"EJ Harris","year":"2025","unstructured":"Harris EJ, Karaoglu DA, Sukhanova M, Abaza Y, Karantanos T, Eisfeld A, et al. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025;15(1):138.","journal-title":"Blood Cancer J"},{"issue":"4","key":"175_CR33","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/bjh.20260","volume":"207","author":"H Pourhassan","year":"2025","unstructured":"Pourhassan H, Tinajero J, Ma H, Jackson R, Pillai R, Ngo D, et al. The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia. Br J Haematol. 2025;207(4):1377\u201387.","journal-title":"Br J Haematol"},{"issue":"12","key":"175_CR34","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","volume":"9","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878\u201385.","journal-title":"Lancet Haematol"},{"issue":"19","key":"175_CR35","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","volume":"130","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017;130(19):2064\u201372.","journal-title":"Blood"},{"issue":"2","key":"175_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/cncr.31848","volume":"125","author":"S Chiaretti","year":"2019","unstructured":"Chiaretti S, Messina M, Fo\u00e0 R. BCR\/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat? Cancer. 2019;125(2):194\u2013204.","journal-title":"Cancer"},{"issue":"1","key":"175_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3324\/haematol.2015.136366","volume":"102","author":"T Herold","year":"2017","unstructured":"Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, et al. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 2017;102(1):130\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"175_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","volume":"35","author":"KG Roberts","year":"2017","unstructured":"Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394\u2013401.","journal-title":"J Clin Oncol"},{"issue":"8","key":"175_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","volume":"132","author":"KG Roberts","year":"2018","unstructured":"Roberts KG, Reshmi SC, Harvey RC, Chen I, Patel K, Stonerock E, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children\u2019s Oncology Group. Blood. 2018;132(8):815\u201324.","journal-title":"Blood"},{"issue":"25","key":"175_CR40","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","volume":"129","author":"SC Reshmi","year":"2017","unstructured":"Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children\u2019s Oncology Group. Blood. 2017;129(25):3352\u201361.","journal-title":"Blood"},{"issue":"10","key":"175_CR41","doi-asserted-by":"publisher","first-page":"E379","DOI":"10.1002\/ajh.26281","volume":"96","author":"E Jabbour","year":"2021","unstructured":"Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, et al. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed\/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study. Am J Hematol. 2021;96(10):E379\u201383.","journal-title":"Am J Hematol"},{"issue":"9","key":"175_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"12","key":"175_CR43","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jtct.2024.09.020","volume":"30","author":"ZA Rahman","year":"2024","unstructured":"Rahman ZA, Othman T, Saliba RM, Moreno Vanegas YA, Mohty R, Ledesma C, et al. A multicenter analysis of allogeneic transplant outcomes in adults with Philadelphia-like B-cell acute lymphoblastic leukemia in first complete remission. Transplant Cell Ther. 2024;30(12):1197\u2013205.","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"175_CR44","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1182\/blood.2023021942","volume":"142","author":"S Shimony","year":"2023","unstructured":"Shimony S, Luskin MR. Unraveling KMT2A-rearranged ALL. Blood. 2023;142(21):1764\u20136.","journal-title":"Blood"},{"issue":"21","key":"175_CR45","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood.2023021501","volume":"142","author":"R Kim","year":"2023","unstructured":"Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, et al. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study. Blood. 2023;142(21):1806\u201317.","journal-title":"Blood"},{"issue":"6","key":"175_CR46","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/JCO.20.02333","volume":"39","author":"J Stutterheim","year":"2021","unstructured":"Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, et al. Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the Interfant-06 protocol. J Clin Oncol. 2021;39(6):652\u201362.","journal-title":"J Clin Oncol"},{"issue":"7","key":"175_CR47","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41375-024-02209-7","volume":"38","author":"T Burmeister","year":"2024","unstructured":"Burmeister T, Str\u00f6h A, Kehden B, Trautmann H, Meyer C, Marschalek R, et al. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia. Leukemia. 2024;38(7):1600\u20133.","journal-title":"Leukemia"},{"issue":"17","key":"175_CR48","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388(17):1572\u201381.","journal-title":"N Engl J Med"},{"issue":"9","key":"175_CR49","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"M O'Brien","year":"2022","unstructured":"O\u2019Brien M, Ji L, Shah N, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40(9):956\u201367.","journal-title":"J Clin Oncol"},{"issue":"6","key":"175_CR50","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","volume":"9","author":"NJ Short","year":"2025","unstructured":"Short NJ, Aldoss I, DeAngelo DJ, Konopleva M, Leonard J, Logan AC, et al. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025;9(6):1442\u201351.","journal-title":"Blood Adv"},{"issue":"19","key":"175_CR51","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1903\u201330.","journal-title":"Blood"},{"issue":"14","key":"175_CR52","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","volume":"7","author":"EC Liang","year":"2023","unstructured":"Liang EC, Dekker SE, Sabile J, Torelli S, Zhang A, Miller K, et al. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation. Blood Adv. 2023;7(14):3395\u2013402.","journal-title":"Blood Adv"},{"issue":"3","key":"175_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood.2023023699","volume":"144","author":"L Muffly","year":"2024","unstructured":"Muffly L, Liang EC, Dolan JG, Pulsipher MA. How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL. Blood. 2024;144(3):253\u201361.","journal-title":"Blood"},{"issue":"6","key":"175_CR54","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10(6):e433\u201344.","journal-title":"Lancet Haematol"},{"issue":"3","key":"175_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajh.27576","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, et al. Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Am J Hematol. 2025;100(3):402\u20137.","journal-title":"Am J Hematol"},{"issue":"21","key":"175_CR56","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1182\/blood.2024027500","volume":"145","author":"R Bassan","year":"2025","unstructured":"Bassan R, Chiaretti S, Starza ID, Santoro A, Spinelli O, Tosi M, et al. Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study. Blood. 2025;145(21):2447\u201359.","journal-title":"Blood"},{"issue":"9","key":"175_CR57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392(9):875\u201391.","journal-title":"N Engl J Med"},{"issue":"4","key":"175_CR58","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137(4):471\u201384.","journal-title":"Blood"},{"issue":"4","key":"175_CR59","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","volume":"7","author":"AJ Lamble","year":"2023","unstructured":"Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023;7(4):575\u201385.","journal-title":"Blood Adv"},{"issue":"10","key":"175_CR60","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","volume":"27","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O\u2019Brien SM, et al. Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin Cancer Res. 2021;27(10):2742\u201354.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"175_CR61","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s00277-021-04601-0","volume":"100","author":"J Reinert","year":"2021","unstructured":"Reinert J, Beitzen-Heineke A, Wethmar K, Stelljes M, Fiedler W, Schwartz S. Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed\/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin. Ann Hematol. 2021;100(11):2727\u201332.","journal-title":"Ann Hematol"},{"issue":"9","key":"175_CR62","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1038\/bcj.2017.89","volume":"7","author":"CL Haddox","year":"2017","unstructured":"Haddox CL, Mangaonkar AA, Chen D, Shi M, He R, Oliveira JL, et al. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A\/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J. 2017;7(9):e607.","journal-title":"Blood Cancer J"},{"issue":"7","key":"175_CR63","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","volume":"6","author":"EM Holland","year":"2022","unstructured":"Holland EM, Yates B, Ling A, Yuan CM, Wang HW, Stetler-Stevenson M, et al. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Adv. 2022;6(7):2167\u201382.","journal-title":"Blood Adv"},{"issue":"10","key":"175_CR64","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","volume":"8","author":"AB Leahy","year":"2021","unstructured":"Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021;8(10):e711\u201322.","journal-title":"Lancet Haematol"},{"issue":"1","key":"175_CR65","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","volume":"19","author":"A Tanguy-Schmidt","year":"2003","unstructured":"Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela J, Hayette S, Vekemans M, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2003;19(1):150\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"36","key":"175_CR66","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42(36):4246\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"175_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01055-1","volume":"14","author":"C Wang","year":"2024","unstructured":"Wang C, Li J, Liu W, Zhao L, Yan H, Yan Y, et al. Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia. Blood Cancer J. 2024;14(1):71.","journal-title":"Blood Cancer J"},{"issue":"10","key":"175_CR68","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole O, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10):491\u2013502.","journal-title":"Lancet"},{"issue":"5","key":"175_CR69","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah BD, Cassaday RD, Park JH, Houot R, Logan A, Boissel N, et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025;39(5):1058\u201368.","journal-title":"Leukemia"},{"issue":"15","key":"175_CR70","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u201363.","journal-title":"Blood"},{"issue":"10","key":"175_CR71","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113\u201322.","journal-title":"Am J Hematol"},{"issue":"5","key":"175_CR72","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.24.00321","volume":"43","author":"GW Roloff","year":"2025","unstructured":"Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, et al. Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL. J Clin Oncol. 2025;43(5):558\u201366.","journal-title":"J Clin Oncol"},{"issue":"9","key":"175_CR73","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","volume":"9","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Li S, Zhang J, Clark MC, Agrawal V, Pourhassan H, et al. TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025;9(9):2159\u201372.","journal-title":"Blood Adv"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00175-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:11:27Z","timestamp":1789459887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00175-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00175-w","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}